Oncternal Therapeutics Inc
NASDAQ:ONCT

Watchlist Manager
Oncternal Therapeutics Inc Logo
Oncternal Therapeutics Inc
NASDAQ:ONCT
Watchlist
Price: 0.5266 USD
Market Cap: $1.6m

Net Margin

-1 600%
Current
Improving
by 2 256.3%
vs 3-y average of -3 856.3%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-1 600%
=
Net Income
$-34.6m
/
Revenue
$2.2m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-1 600%
=
Net Income
$-34.6m
/
Revenue
$2.2m

Peer Comparison

Country Company Market Cap Net
Margin
US
Oncternal Therapeutics Inc
NASDAQ:ONCT
1.6m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
388.1B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.8B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
173.5B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
122B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
86.9B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Lower than 95% of companies in the United States of America
Percentile
5th
Based on 15 072 companies
5th percentile
-1 600%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Oncternal Therapeutics Inc
Glance View

Market Cap
1.6m USD
Industry
Biotechnology

Oncternal Therapeutics, Inc. engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. The company is headquartered in San Diego, California and currently employs 26 full-time employees. The company went IPO on 2004-02-03. The firm is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. Its product candidates include Zilovertamab, ONCT-808, ONCT-534 and ONCT-216. Zilovertamab is an investigational, humanized, monoclonal antibody designed to inhibit Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1), a growth factor receptor that is expressed on many tumors and that activates pathways to increased tumor proliferation, invasiveness and drug resistance, and bind to a specific functionally important epitope of ROR1. ONCT-808 is an autologous chimeric antigen receptor (CAR-T) therapy that targets ROR1 for the treatment of hematologic malignancies and solid tumors. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of advanced castration-resistant prostate cancer (CRPC) and other androgen receptor (AR) driven diseases.

ONCT Intrinsic Value
1.7561 USD
Undervaluation 70%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-1 600%
=
Net Income
$-34.6m
/
Revenue
$2.2m
What is Oncternal Therapeutics Inc's current Net Margin?

The current Net Margin for Oncternal Therapeutics Inc is -1 600%, which is above its 3-year median of -3 856.3%.

How has Net Margin changed over time?

Over the last 3 years, Oncternal Therapeutics Inc’s Net Margin has decreased from -482.8% to -1 600%. During this period, it reached a low of -6 330% on Sep 30, 2023 and a high of -482.8% on Aug 30, 2021.

Back to Top